4.7 Review

Adiponectin actions in the cardiovascular system

期刊

CARDIOVASCULAR RESEARCH
卷 74, 期 1, 页码 11-18

出版社

OXFORD UNIV PRESS
DOI: 10.1016/j.cardiores.2006.10.009

关键词

diabetes; epidemiology; heart failure; remodeling; protein kinases

资金

  1. NHLBI NIH HHS [HL81587, HL77774, HL86785, R01 HL086785, R01 HL077774, P01 HL081587] Funding Source: Medline
  2. NIA NIH HHS [R37 AG015052, AG15052, R01 AG015052] Funding Source: Medline
  3. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077774, P01HL081587, R01HL086785] Funding Source: NIH RePORTER
  4. NATIONAL INSTITUTE ON AGING [R01AG015052, R37AG015052] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Obesity is strongly associated with the pathogenesis of type 2 diabetes, hypertension, and cardiovascular disease. Levels of the hormone adiponectin are downregulated in obese individuals, and several experimental studies show that adiponectin protects against the development of various obesity-related metabolic and cardiovascular diseases. Adiponectin exhibits favorable effects on atherogenesis, endothelial function, and vascular remodeling by modulation of signaling cascades in cells of the vasculature. More recent findings have shown that adiponectin directly affects signaling in cardiac cells and is beneficial in the setting of pathological cardiac remodeling and acute cardiac injury. Several of these effects of adiponectin have been attributed to the activation of the 5' AMP-activated protein kinase signaling cascade and other signaling proteins. This review will discuss the epidemiological and experimental studies that have elucidated the role of adiponectin in a variety of cardiovascular diseases. (c) 2006 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据